A Study of the Safety, Tolerability, and Absorption, Metabolism, and Excretion of PA-824 in Healthy Adult Male Subjects.
Status:
Completed
Trial end date:
2006-05-01
Target enrollment:
Participant gender:
Summary
This study is a Phase 1, single-center, open-label, single-dose study to evaluate (1) the
absorption, metabolism, and excretion patterns of a single dose of [14C] PA-824, and (2) the
pharmacokinetics, safety, and tolerability of a single oral-suspension dose of unlabeled
PA-824 in healthy adult male subjects. Unlabeled PA-824 and [14C]-PA-824 will be administered
together in an oral-suspension formulation. Enrollment is planned for one dose group of 6
subjects. All 6 subjects will receive the same treatment.